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Abstract Alzheimer’s disease (AD) and vascular dementia
(VaD) are the most common causes of dementia, and border-
lines are blurred in many cases. Aging remains the main risk
factor to suffer dementia; however, epidemiological studies
reveal that diabetes may also predispose to suffer AD. In order
to further study this relationship, we have induced
hypoinsulinemic diabetes to APPswe/PS1dE9 (APP/PS1)
mice, a classical model of AD. APP/PS1 mice received
streptozotocin (STZ) ip at 18 weeks of age, when AD pathol-
ogy is not yet established in this animal model. Cognition was
evaluated at 26 weeks of age in the Morris water maze and the
new object discrimination tests. We observed that STZ-
induced episodic and working memory impairment was sig-
nificantly worsened in APP/PS1 mice. Postmortem assess-
ment included brain atrophy, amyloid-beta and tau patholo-
gy, spontaneous bleeding, and increased central inflamma-
tion. Interestingly, in APP/PS1-STZ diabetic mice, we de-
tected a shift in Aβ soluble/insoluble levels, towards more
toxic soluble species. Phospho-tau levels were also increased
in APP/PS1-STZ mice, accompanied by an exacerbated in-
flammatory process, both in the close proximity to senile
plaque (SP) and in SP-free areas. The presence of hemor-
rhages was significantly higher in APP/PS1-STZ mice, and
although pericytes and endothelium were only partially
affected, it remains possible that blood-brain barrier alter-
ations underlie observed pathological features. Our data sup-
port the implication of the diabetic process in AD and VaD,
and it is feasible that improving metabolic control could
delay observed central pathology.
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Background
Alzheimer’s disease (AD) and vascular dementia (VaD) are
the first and second most common causes of dementia respec-
tively. Moreover, the borderlines between them are blurred,
since in many cases, traditional AD hallmarks coexist with
markers of vascular injury [1]. AD pathological features in-
clude senile plaque (SP), composed by amyloid-beta (Aβ) 40
and 42, neurofibrillary tangles formed by abnormally phos-
phorylated tau, and synaptic and neuronal loss [2]. On the
other hand, VaD is a heterogeneous disease that includes
microinfarcts, small vessel ischemic disease, or microvascular
injury [1].
Aging remains the main risk factor to suffer AD how-
ever, the fact that most of the cases are sporadic has fa-
vored the study of other risk factors, among which diabe-
tes plays a relevant role. Impaired insulin secretion and
resistance, as well as glucose intolerance, seem to be as-
sociated with increased risk of AD [3–5]. Insulin and in-
sulin receptors are widely distributed in regions implicated
in learning and memory, such as the cortex and hippocam-
pus, and previous studies have reported cognition impair-
ment in type 1 diabetic children [6, 7]. Also, AD brains
present lower insulin levels and higher insulin receptor
density when compared to control patients (for a review,
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see [8]). It has also been shown that insulin dysregulation
may interfere with AD neuropathological features, and in-
sulin exacerbation of inflammatory responses may interact
with Aβ processing and deposition (for review, see [9,
10]). Tau phosphorylation is also severely affected when
insulin levels are altered [11–13], and sequential phosphor-
ylated residues have been characterized when insulin levels
are reduced [14]. Insulin participates in neurovascular con-
trol, and therefore, it may relate metabolic alterations to
VaD [15]. Also, vascular damage has been suggested to
reduce Aβ clearance along interstitial fluid drainage path-
ways [16, 17] linking diabetes, AD and VaD. Following
this idea, the beneficial effect of intranasal insulin on cog-
nitive function in AD patients has been reported [18, 19].
In order to further explore the relationship between meta-
bolic alterations, as insulin deprivation and derived hyper-
glycemia, and AD-VaD central pathology, we have induced
type 1 diabetes (T1D) to a classical model of AD. We
injected STZ to APP/PS1mice before Aβ deposition com-
mences, at around 4 months of age, and we have observed
a significant worsening effect of cognitive abilities, includ-
ing episodic memory, by 6 months of age, when Aβ de-
position is established in APP/PS1 mice [20]. As previous-
ly described, tau phosphorylation was significantly in-
creased, both in the cortex and hippocampus from APP/
PS1-STZ mice. Interestingly, a shift in Aβ soluble/
insoluble levels was observed, with increased soluble,
more toxic, species found in APP/PS1-STZ mice, accom-
panied by reduced insoluble Aβ levels and deposited am-
yloid. Also, inflammation was exacerbated, and increased
microglial activation was observed in APP/PS1-STZ mice.
Moreover, we observed that hemorrhage burden was wors-
ened in APP/PS1-STZ mice, in relevant regions for learn-
ing and memory, suggesting that alterations in the blood-
brain barrier may be responsible for the pathological fea-
tures detected in APP/PS-STZ mice.
Results
Metabolic Characterization
No differences were detected in any of the parameters under
study before administering STZ (18 weeks) (body weight F(3,
33)=0.691, p=0.564, glucose F(3,33)=1.49, p=0.234, and in-
sulin F(3,33)=0.773, p=0.518) (Table 1). As it could be expect-
ed, 8 weeks after STZ treatment, we observed that metabolic
parameters were significantly altered, resembling T1D with
poor metabolic control. A slight reduction in body weight
was observed in STZ-treated mice, although differences did
not reach statistical significance (F(3,33)=0.691, p=0.564).
Glucose levels were significantly increased in STZ-treated
mice and this effect was worsened in APP/PS1-STZ mice
(F(3,28) =60.26, **p<0.01 vs. the rest of the groups,
**p<0.01 vs. Wt-Sham and APP/PS1-Sham) (Table 1). Insu-
lin levels were significantly reduced in STZ-treated mice, both
Wt and APP/PS1 groups (F(3,28)=54.59, ††p<0.01 vs. Wt-
Sham and APP/PS1-Sham) (Table 1).
Learning and Memory Assessment
In order to evaluate episodic memory, we performed the new
object discrimination (NOD) test as previously described [21].
To our knowledge, episodic memory in a mixed model of
T1D-AD has not been assessed before. We observed an over-
all cognitive decline in wild-type mice treated with STZ, with
comparable performance to APP/PS1-Sham treated mice, and
a worsening effect was observed in APP/PS1-STZ mice.
Whereas no differences were observed among groups in the
Bwhen^ paradigm (F(3,83)=1.39, p=0.251), a slight impair-
ment was observed in Wt-STZ, APP/PS1-Sham, and APP/
PS1-STZ groups, when compared with Wt-Sham animals
(F(3,83)=1.39, p=0.251). On the other hand, a significant im-
pairment was observed in the Bwhat^ paradigm, in the case of
Table 1 Metabolic characterization of STZ-treated mice













Wt-Sham 27.96±2.18 27.98±2.03 149.99±4.78 150.33±4.78 0.63±0.04 0.57±0.01
Wt-STZ 29.27±1.81 23.31±2.06 135.22±8.54 450.33±41.95†† 0.65±0.04 0.23±0.03††
APP/PS1-Sham 25.75±1.98 25.08±2.24 125.25±10.02 123.57±5.40 0.60±0.02 0.56±0.02
APP/PS1-STZ 28.50±1.35 23.46±1.37 125.50±6.97 562.10±21.10** 0.67±0.03 0.23±0.02††
No differences were detected in any of the parameters under study before administering STZ (18 weeks): body weight (p=0.564), glucose (p=0.234),
and insulin (p=0.518). Metabolic parameters were significantly affected at 26 weeks; after STZ treatment, glucose was increased in Wt-STZ mice, and
even higher increases were observed in APP/PS1-STZ mice (**p<0.01 vs. the rest of the groups, ††p<0.01 vs. Wt-Sham and APP/PS1-Sham), insulin
was significantly reduced in STZ-treated mice (††p<0.01 vs. Wt-Sham and APP/PS1-Sham), and whereas body weight was slightly reduced in STZ-
treated mice, differences did not reach statistical significance (p=0.35). Data are representative of 6–11 mice and differences were detected by one-way
ANOVA for independent samples followed by Tukey b or Tamhane tests as required
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APP/PS1-Sham and Wt-STZ animals, and a worsening effect
was observed in APP/PS1-STZ-treated mice (F(3,83)=15.18,
**p<0.01 vs. the rest of the groups, ‡‡p<0.01 vs. Wt-Sham)
(Fig. 1a). A similar profile was observed for the Bwhere^
paradigm (F(3,83)=27.34, **p<0.01 vs. the rest of the groups,
‡‡p<0.01 vs. Wt-Sham) (Fig. 1a).
We also evaluated spatial memory in the Morris wa-
ter maze (MWM) test, and we detected a significant
group × day effect along the acquisition phase, by
two-way ANOVA (F(9,465)=1.92, *p=0.04). Further as-
sessment of individual days revealed an overall increase
in the required time to locate the platform for Wt-STZ
and APP/PS1-Sham mice, and a worsening effect in
APP/PS1-STZ mice, that was especially relevant during
the last day of the acquisition phase (day 1 F(3,124)=
1.667, p=0.177, day 2 F(3,124)=7.24, ‡‡p<0.01 vs.
Wt-Sham, day 3 F(3,124)=9.48, ‡‡p<0.01 vs. Wt-Sham,
day 4 F(3,121)=21.43, **p<0.01 vs. the rest of the
groups, ‡‡p<0.01 vs. Wt-Sham] (Fig. 1b). Similar
memory impairment was observed during the retention
phase. In retention 1 (24 h after completing the acqui-
sition phase), we observed a reduction in the time that
APP/PS1-STZ mice spent in the quadrant (quadrant 2)
where the platform used to be located (F(3,26)=4,93
‡‡p=0.008 vs. Wt-Sham) (Fig. 1c). On the second re-
tention phase (72 h after completion of the acquisition
phase), we observed that memory dysfunction was sta-
tistically significant in the Wt-STZ group, and cognitive
impairment was worsened in APP/PS1-STZ animals
(F(3,24)=45.13, ††p=0.006 vs. Wt-Sham and APP/PS1-
Sham, ‡‡p<0.01 vs. Wt-Sham) (Fig. 1c).
We analyzed motor activity in all animals under study by
measuring locomotor activity in the open field, and no differ-
ences among groups were observed when we compared the
distances in the proximity of the walls (F(3,25)=1.34, p=
0.283) or in the center of the arena, indicative of anxiety-like
behavior (F(3,25)=1.33, p=0.285) (Table 2). Swimming speed
in the MWM also remained unaltered (F(3,26)=0.822, p=
0.494). Similarly, final speed in the rotarod test was not affect-
ed in any of the groups under study (F(3,24)=1.75, p=0.183).
Motor activity or anxiety-related paradigms were unaffected
(Table 2), supporting that our observations in learning and
memory were not due to motor function limitations. Altogeth-
er, our data suggest the presence of cognitive impairment both
in AD (APP/PS1-Sham) and diabetic (Wt-STZ) mice, with a
synergistic effect in APP/PS1-STZ mice, supporting a cross-
talk between both pathology types that worsens episodic and
spatial memory.
Fig. 1 Learning and memory activities are impaired in APP/PS1-STZ
mice. a The NOD test revealed that episodic memory was compromised
in APP/PS1-Sham and Wt-STZ mice and this effect was worsened in
APP/PS1-STZ mice for Bwhat^ (**p<0.01 vs. the rest of the groups,
‡‡p<0.01 vs. Wt-Sham) and Bwhere^ (**p<0.01 vs. the rest of the
groups, ‡‡p<0.01 vs. Wt-Sham), whereas differences did not reach sta-
tistical significance in the case of the Bwhen^ paradigm (p=0.251). b
Spatial learning and memory were also affected in the MWM test, and
a significant group × day effect was detected by two-way ANOVA for
independent samples (*p=0.04). Further daily assessment revealed that
learning was significantly compromised along the acquisition phase in
APP/PS1-Sham andWt-STZ mice, and this effect was worsened in APP/
PS1-STZ mice (day 1 p=0.177, day 2 ‡‡p<0.01 vs. Wt-Sham, day 3
‡‡p<0.01 vs. Wt-Sham, and day 4 **p<0.01 vs. the rest of the groups,
‡‡p<0.01 vs.Wt-Sham). cA significant impairment was also observed in
APP/PS1-STZ mice on the retention 1 (24 h after acquisition) (‡‡p<0.01
vs. Wt-Sham). On retention 2 (72 h after acquisition), we observed an
overall worse performance in all groups; Wt-STZ mice were significantly
impaired and this effect was exacerbated in APP/PS1-STZ mice
(††p<0.01 vs. Wt-Sham and APP/PS1-Sham, ‡‡p<0.01 vs. Wt-Sham).
Data are representative of 6–9mice and differences were detected by one-
way ANOVA followed by Tukey b or Tamhane tests as required
Mol Neurobiol (2016) 53:2685–2697 2687
Brain Morphology
Brain weight was significantly reduced in STZ-treated mice
and APP/PS1-STZ mice were more severely affected, al-
though no differences were detected when compared with
wild-type STZ-treated animals (F(3,26)=7.18, ††p<0.01 vs.
Wt-Sham and APP/PS1-Sham) (Fig. 2a). Since brain weight
is a very rough approximation to measure brain atrophy, cresyl
violet staining was performed on brain hemisections and cor-
tical and hippocampal sizes were measured along the hemi-
sphere. We detected that hippocampal areas were slightly re-
duced in STZ-treated mice, although no statistical differences
were observed (−1.5 mm [F(3,13)=0.780, p=0.526], −2.5 mm
[F(3,14)=1.33, p=0.303], −3.5 mm [F(3,14)=21.38, p=0.289],
at least at this stage of the disease (Fig. 2b)). An overall re-
duction in cortical size was observed in STZ-treated mice,
especially evident in APP/PS1-STZ mice (1.5 mm [F(3,14)=
41.55, p=0.244], 0.5 mm [F(3,13)=3.30, p=0.054], −0.5 mm
[F(3,13)=7.84, ††p=0.003 vs. Wt-Sham and APP/PS1-Sham],
−1.5 mm [F(3,13)=15.24, ††p<0.001 vs. Wt-Sham and APP/
PS1-Sham], −2.5 mm [F(3,13)=7.84, †p=0.003 vs. Wt-Sham
and APP/PS1-Sham], and −3.5 mm [F(3,14)=2.64, p=0.09])
(Fig. 2c, d).
The specific effect of the atrophy process on neurons was
also assessed, and the percentage of neuronal nuclei (NeuN)-
positive cells was significantly reduced in STZ-treated mice,
both in wild-type and APP/PS1mice (Fig. 2e). The percentage
of NeuN-positive cells was lower in the proximity of SP, and
APP/PS1-STZ mice presented even lower densities when
compared with APP/PS1-Sham mice (Fig. 2e).
Amyloid-Beta Pathology
In order to determine the effect of STZ on Aβ pathology, we
quantified SP in the cortex and hippocampus of APP/PS1-
Sham and APP/PS1-STZ mice. We randomly stained wild-
type sections (from Sham and STZ-treated mice), and no
SPs were detected by immunohistochemistry with 4G8
Table 2 No differences in motor function were observed among groups
Distance of outer arena (cm) Distance of inner arena (cm) Swimming speed (cm/s) Rotarod final speed (rpm)
Wt-Sham 4389.88±612.29 702.47±57.64 13.02±0.82 23.17±2.15
Wt-STZ 3628.93±245.72 646.58±48.45 11.48±0.93 17.67±1.69
APP/PS1-Sham 4709.50±510.19 783.09±63.64 11.19±0.58 16.00±2.82
APP/PS1-STZ 4693.93±373.25 759.09±42.62 11.74±0.82 16.67±2.29
No differenceswere observed in any of the parameters under study (distance of outer arena, p=0.283; distance of inner arena, p=0.285; swimming speed,
p=0.494; rotarod final speed, p=0.183)
Fig. 2 Significant brain atrophy is observed after STZ administration. a
We observed a reduction of brain weight in Wt-STZ and APP/PS1-STZ-
treated mice, at 26 weeks of age (††p<0.01 vs. Wt-Sham and APP/PS1-
Sham). b Hippocampal assessment revealed a slight reduction in APP/
PS1-STZ-treated mice, although differences did not reach statistical sig-
nificance (−1.5 mm, p=0.526; −2.5 mm, p=0.303; −3.5 mm, p=0.289). c
Further assessment of cortical brain sections revealed an overall reduction
of cortex size after STZ treatment, that was slightly worsened in APP/PS1
mice. Cortical size reduction reached statistical significance at −0.5, −1.5,
and −2.5 mm from bregma (††p<0.01 vs. wild type and APP/PS1). d
Illustrative images of cortical size and thickness, stained with cresyl
violet, in all groups under study, where significant shrinkage can be ob-
served in STZ-treated mice. Green lines point at cortical thickness (Wt-
Sham=1.006 mm, Wt-STZ=0.887 mm, APP/PS1-Sham=0.96 mm, and
APP/PS1-STZ=0.825 mm). Scale bar=250 μm. e A significant reduc-
tion in the proportion of neurons was observed in wild-type-STZ mice far
from plaques, and this effect was worsened in APP/PS1-STZ mice
(F(3,596)=11.27, ††p<0.01 vs.Wt-Sham andAPP/PS1-Sham). An overall
reduction in proportion of NeuN-positive cells was observed in the prox-
imity to senile plaques, and this effect was more severe in APP/PS1-STZ-
treated mice (**p=0.001 vs. APP/PS1 Sham)
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antibody or staining with thioflavin S (TS) (Fig. 3b). SP bur-
den was slightly reduced in the cortex from APP/PS-STZ
mice after 4G8 immunohistochemistry, although differences
just missed statistical significance (p=0.052) (Fig. 3a, b). As
in previous studies [20], the overall SP size was not altered
(APP/PS1-Sham 273.84±7.64 μm2 and APP/PS1-STZ
267.46±8.11 μm2, p=0.571), supporting the idea that SP size
is stable once deposited [17, 22]. A slight, non-significant,
reduction in the number of SP per square millimeter was de-
tected in APP/PS1-STZ-treatedmice (APP/PS1-Sham 17.78±
1.23 SP/mm2 and APP/PS1-STZ 14.99±1.04 SP/mm2, p=
0.089). When dense-core SP burden was measured after TS
staining, we observed a significant reduction of affected cor-
tical area in APP/PS1-STZ-treated mice (**p<0.01 vs. APP/
PS1-Sham) (Fig. 3a). As expected in this animal model, SP
burden was lower in the hippocampus, and although we ob-
served a similar trend to that described in the cortex, differ-
ences did not reach statistical significance when SP deposits
inmunostained with 4G8 were quantified (p=0.272) (Fig. 3a).
Similarly, neither 4G8 deposits size (APP/PS1-Sham 232.58±
15.73 μm2 and APP/PS1-STZ 253.85±22.62 μm2, p=0.432)
or number per square millimeter (/PS1-Sham 7.79±1.40 μm2
and APP/PS1-STZ 5.29±0.86 μm2, p=0.147) was affected in
the hippocampus. TS deposits also reproduced this profile (p=
0.577) (Fig. 3a). We observed a similar effect when cerebral
amyloid angiopathy (CAA) was quantified, and a reduction of
CAA was observed in APP/PS1-STZ mice (*p=0.022 vs.
APP/PS1-Sham) (Fig. 3c). Immunohistochemistry
observations were corroborated by Aβ ELISA studies. As
expected, Aβ levels were significantly increased in APP/
PS1 mice, when compared with wild-type animals, and no
differences were observed between wild-type or wild-type-
STZ-treated mice. Whereas an increase of soluble Aβ40
[F(3,10) =39.50, **p<0.01 vs. the rest of the groups,
††p<0.01 vs. wild type and wild-type-STZ] and Aβ42 [F(3,
10)=143.81, **p<0.01 vs. the rest of the groups, ††p<0.01 vs.
wild type and wild-type-STZ] levels was observed in the cor-
tex from APP/PS1-STZ-treated mice (Fig. 3D), a reduction of
insoluble species was observed in APP/PS1-STZ-treated mice
(Aβ40 [F(3,9)=61.34, **p<0.01 vs. the rest of the groups,
††p<0.01 vs. wild type and wild-type-STZ], Aβ40 [F(3,10)=
22.04, **p<0.01 vs. the rest of the groups, ††p<0.01 vs. wild
type and wild-type-STZ]) (Fig. 3d). A similar profile was
observed in the hippocampus although differences only
reached statistical significance when Aβ40 species were com-
pared, both in the case of soluble (Aβ40 [F(3,10)=81.93,
**p<0.01 vs. the rest of the groups, ††p<0.01 vs. wild type
and wild-type-STZ], Aβ42 [F(3,10)=18.513, ††p<0.01 vs.
wild type and wild-type-STZ]) (Fig. 3d) and insoluble Aβ
levels ([F(3,10)=164.24, **p<0.01 vs. the rest of the groups,
††p<0.01 vs. wild type and wild-type-STZ], Aβ42 [F(3,10)=
21.93, ††p<0.01 vs. wild type and wild-type-STZ]). These
data suggest a shift between soluble-insoluble Aβ spe-
cies in APP/PS1-STZ-treated mice that might be due to
alterations in any of the steps implicated in Aβ produc-
tion or clearance.
Fig. 3 Cortical and hippocampal amyloid pathology after STZ treatment.
a A slight reduction of cortical SP burden was observed after STZ
treatment, although differences only reached statistical significance in
the case of TS staining (4G8 p=0.085, TS **p<0.01 vs. APP/PS1-
Sham). A similar profile was observed in the hippocampus although no
statistical differences were detected (4G8 p=0.272, TS p=0.577). b
Illustrative example of TS staining (green) and 4G8 (red)
immunostaining in wild-type-Sham, wild-type-STZ, APP/PS1-Sham,
and APP/PS1-STZ mice. Scale bar=200 μm. c CAA burden was also
slightly lower in APP/PS1-STZ mice (*p=0.022 vs. APP/PS1). Illustra-
tive images of leptomeningeal vessels with CAA stained with 4G8. Scale
bar=100 μm. d Soluble Aβ40 and 42 levels were increased both in the
cortex and hippocampus from APP/PS1-STZ-treated mice (cortex Aβ40
**p<0.01 vs. the rest of the groups, ††p<0.01 vs. wild-type-Sham and
wild-type-STZ, Aβ42 **p<0.01 vs. the rest of the groups, ††p<0.01 vs.
wild-type-Sham and Wild-type-STZ; hippocampus Aβ40 **p<0.01 vs.
the rest of the groups, ††p<0.01 vs. wild-type-Sham and wild-type-STZ,
Aβ42 ††p<0.01 vs. wild-type-Sham and wild-type-STZ). On the other
hand, insoluble Aβ40 and 42 levels were reduced in APP/PS1-STZ mice
when compared to sham-treated animals both in the cortex (Aβ40,
**p<0.01 vs. the rest of the groups, ††p<0.01 vs. wild-type-Sham and
wild-type-STZ; Aβ42, **p<0.01 vs. the rest of the groups, ††p<0.01 vs.
wild-type-Sham and wild-type-STZ) and the hippocampus (Aβ40,
**p<0.01 vs. the rest of the groups, ††p<0.01 vs. wild-type-Sham and
wild-type-STZ; Aβ42, ††p<0.01 vs. wild-type-Sham and wild-type-
STZ). e Phospho-tau/total tau ratio was significantly increased in APP/
PS1-STZ-treated mice both in the cortex (††p=0.003 vs. wild-type-Sham
and APP/PS1-Sham) and in the hippocampus (†p=0.011 vs. wild-type-
Sham and APP/PS1-Sham). f Illustrative example of cortical tau phos-
phorylation in wild-type-Sham, wild-type-STZ, APP/PS1-Sham, and
APP/PS1-STZ mice
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Tau Pathology
Wemeasured the ratio of phospho-tau/total tau levels byWest-
ern blot. A slight increase in cortical phospho-tau/total tau
ratio was observed in APP/PS1-Sham and Wt-STZ mice, al-
though differences only reached statistical significance in
APP/PS1-STZ-treated mice (F(3,26)=5.91, ††p=0.003 vs.
Wt-Sham and APP/PS1-Sham) (Fig. 3e, f). A similar profile
was observed in the hippocampus (F(3,27)=4.51, †p=0.011 vs.
Wt-Sham and APP/PS1-Sham) (Fig. 3e). Our data are in ac-
cordance with previous studies where significant alterations,
in central tau phosphorylation, are observed after STZ diabe-
tes induction [11, 14, 23].
IDE and Neprilysin
When we analyzed central levels of enzymes implicated in
insulin and Aβ degradation, we did not observe any alter-
ations in the cortex or the hippocampus from any of the groups
under study (Table 3). After STZ treatment, insulin degrading
enzyme (IDE) levels were unaltered in the cortex (F(3,14)=
0.87, p=0.47) or the hippocampus (F(3,14)=0.054, p=0.98),
and a similar outcome was observed when neprilysin levels
were compared (cortex F(3,14)=10.46, p=0.709, hippocampus
F(3,14)=0.54, p=0.659), suggesting that these enzymes are not
affected after treatment (Table 3).
Microglial Activation
We analyzed the inflammatory process by quantifying
microglial immunostaining with iba-1 antibody. We observed
that microglial burden was slightly increased in the cortex
from APP/PS1-Sham mice even far from plaques, and this
effect was more pronounced in Wt-STZ-treated mice. Inflam-
matory process far from plaques was significantly worsened in
APP/PS1-STZ-treated mice (F(3,1382)=42.25, **p=0.01 vs.
the rest of the groups, ‡‡p<0.01 vs. Wt-Sham) (Fig. 4a, c),
supporting a synergistic effect between diabetes and AD at
this level. When we analyzed microglial burden in the close
proximity of SP, we also observed that the inflammatory
process was favored in APP/PS1-STZ mice (**p<0.01 vs.
APP/PS1-Sham) (Fig. 4a, c). A similar profile was observed
in the hippocampus, both far (F(3,272)=42.26.45, **p<0.01
vs. the rest of the groups, ‡‡p<0.01 vs. Wt-Sham) and close
to SP (*p<0.04 vs. APP/PS1-Sham) (Fig. 4b), supporting an
overall increase of microglia in the hippocampus.
Effect of STZ on Brain Vascular Pathology
We observed an increase of hemorrhage burden in the cortex
from STZ-treated mice, and this effect was worsened in APP/
PS1 animals (F(3,198)=15.81, **p<0.01 vs. the rest of the
groups, ††p<0.01 vs. Wt-Sham and APP/PS1-Sham). Indi-
vidual hemorrhage size was similar among groups (F(3,
1002)=0.69) although the number of hemorrhages per square
millimeter was significantly increased in APP/PS1-STZ mice
(F(3,207)=27.25, **p<0.01 vs. the rest of the groups,
††p<0.01 vs.Wt-sham and APP/PS1-Sham) (Fig. 5a, c). The-
se observations support a synergistic effect between diabetes
and AD pathology. Hippocampal studies revealed a similar
outcome to a more moderate extent, supporting the preferen-
tial affectation of the cortex (hemorrhage burden [F(3,71)=
5.61, ††p<0.01 vs. Wt-sham and APP/PS1-Sham], individual
hemorrhage size [F(3,260)=0.061], and number of hemor-
rhages/mm2 [F(3,79)=10.09, ††p<0.01 vs. Wt-sham and
APP/PS1-Sham]) (Fig. 5b). Endothelial cells and pericyte
densities were slightly reduced in APP/PS1-STZ mice, al-
though differences did not reach statistical significance (endo-
thelium [F(3,66)=0.511, p=0.676], pericytes [F(3,59)=
0.760, p=0.521]) (Fig. 5c).
Discussion
Previous clinical and epidemiological studies support the role
of metabolic disorders, including midlife hypercholesterol-
emia or metabolic syndrome, as risk factors to suffer AD
[24–27]. It has been reported that insulin plays a relevant role
in central nervous system normal activity and that alterations
of insulin-dependent functions could be related to central
Table 3 Insulin degrading enzyme (IDE) and neprilysin were not affected by STZ treatment
Cortex Hippocampus
IDE (% Wt-Sham) NEP (% Wt-Sham) IDE (% Wt-Sham) NEP (% Wt-Sham)
Wt-Sham 100.00±5.45 100.00±8.39 100.00±14.16 100.00±2.96
Wt-STZ 93.60±10.12 99.94±14.00 97.33±19.37 110.12±11.45
APP/PS1-Sham 79.96±17.76 87.55±10.37 90.46±4.62 96.62±11.19
APP/PS1-STZ 106.39±6.93 106.02±10.90 98.60±31.04 109.76±5.57
No differences were detected when IDE and neprilysin levels were analyzed after STZ treatment in the cortex (IDE p=0.47, neprilysin p=0.709) or the
hippocampus (IDE p=0.98, neprilysin p=0.659)
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pathological features observed in AD [1, 9, 28]. Following
this idea, alterations in insulin levels, such as those observed
in T1D [29] and in T2D [3, 5, 30, 31], have been related to AD
and VaD. In order to further study this relationship, STZ has
been widely used as an alternative model to induce sporadic
AD, by central icv administration (for review, see [32]). How-
ever, the studies on the relationship between STZ-induced
diabetes and AD-VaD alterations have been scarcer.
Our observations in the Morris water maze test are in ac-
cordance with previous studies in diabetic models [33, 34].
We detected spatial memory alterations in APP/PS1-Sham
mice as well as in Wt-STZ-treated mice, and these effects
were worsened in APP/PS1-STZ mice, both during the acqui-
sition and retention phases, suggesting a synergistic effect
between diabetes and AD. Previous studies have reported that
STZ-induced diabetes may interfere with conditioned fear
memory or induce anxiety-like behavior in rodents [35, 36];
however, the fact that we did not observe any motor function
alterations or anxiety-related behavior supports that cognitive
impairment was not secondary to other central behavioral lim-
itations. In order to further explore cognitive alterations, we
explored episodic memory by a demanding approach looking
at three aspects of novel object exploration Bwhat,^ Bwhere,^
and Bwhen.^ As far as we know, episodic memory has not
been assessed in this animal model before, and we found an
overall significant impairment when we analyzed object,
place, and temporal order memory in APP/PS1-STZ mice.
In our hands, AD develops with greater certainty and severity
after insulin deficiency/diabetes gets established. Previous
neuropsychological studies in patients have revealed that ep-
isodic memory is early affected in the dementia process and
that the diabetic process is associated with lower levels of
global cognition [37]. Following this idea, general intelligence
decline or vocabulary impoverishment has also been observed
(for review, see [38]).
STZ treatment induced central atrophy both in APP/PS1
and wild-type mice. Brain weight was reduced and a signifi-
cant reduction of cortical size was also detected. Similar ob-
servations have been previously reported in different models
of diabetes [11, 39, 40]. Whereas we did not try to rescue
observed abnormalities by insulin supplementation, promis-
ing effects have been reported in pilot clinical trials with AD
patients [18]. Also, insulin replacement has been shown to
successfully recover observed abnormalities in T1D mice
[19] or in metabolically impaired AD transgenic mice [41],
and therefore, this is a relevant line that should be further
explored. Our data are in accordance with studies in T1D
patients, where frontal gray matter atrophy or cortical thinning
has been reported [42, 43]. It also seems that smaller brain
volumes are observed in adults with early onset of diabetes,
and since T1D commonly debuts at early age, it is feasible that
modifications in regular brain development may also
Fig. 4 Microglial activation in STZ-treated mice. a Microglial burden
was significantly increased in SP-free areas in the cortex from APP/PS1-
Sham and Wt-STZ-treated mice. Moreover, this effect was worsened in
APP/PS1-STZ-treated mice (**p=0.01 vs. the rest of the groups,
‡‡p<0.01 vs. Wt-Sham). Microglial burden in close proximity to SP
was significantly higher in APP/PS1-STZ-treated mice (**p<0.01 vs.
APP/PS1-Sham). b A similar profile was observed in the hippocampus,
where increased microglial burden in SP-free areas fromWt-STZ-treated
mice was worsened in APP/PS1-STZ-treated animals (**p<0.01 vs. the
rest of the groups, ‡‡p<0.01 vs. Wt-Sham). In the proximity of SP,
microglial burden was significantly higher in APP/PS1-STZ mice
(*p<0.04 vs. APP/PS1-Sham). c Illustrative examples of cortical
microglial immunostaining using anti-microglia (iba 1, green) and anti-
Aβ (4G8, red) where increasedmicroglial burden can be detected inAPP/
PS1-STZ mice, both in proximity to and far from SP. Scale bar=125 μm
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contribute to brain alterations observed in adulthood (for re-
view, see [44]). However, in one-time imaging studies, it is
hard to determine which area is earlier or more severely af-
fected, and longitudinal imaging studies in T1D patients
would be needed to fully understand the role of T1D in brain
atrophy. We further analyzed neuronal loss in STZ mice and
an overall reduction in the percentage of NeuN-positive cells
was observed. We cannot obviate that STZ is toxic, and there-
fore, specific central action cannot be excluded; however, the
synergistic effect observed in the close proximity to SP in
APP/PS1-STZ mice supports a cross-talk between AD and
diabetes, as previously described by other groups with similar
experimental approaches (for review, see [45]).
When we analyzed AD-related central pathology, we ob-
served a dramatic increase in the phospho-tau/total tau ratio in
APP/PS1-STZ-treated mice, both in the cortex and the hippo-
campus. Studies on 3xTg-AD mice have shown no effect on
tau phosphorylation after STZ administration [23]; however,
other groups have reported similar findings to ours, in APP/
PS1 mice [46], and also increased tau phosphorylation has
been observed in different diabetic models (for review, see
[10]). Moreover Clodfelder-Miller et al. have sequentially
characterized affected phosphorylated tau residues after insu-
lin depletion induced by STZ [14]. They also showed that the
process leading to increased tau phosphorylation is insulin
dependent, since insulin administration after short-term insu-
lin deficiency reduced tau hyperphosphorylation at selective
sites [14]. It has also been described that STZ administration
may accelerate amyloid pathology in APP mice by increasing
total Aβ levels and SP [46]. This effect might be mediated by
AGEs/RAGE/NF-κB pathway modulation [47], and en-
hanced APP processing has also been reported in this and
other AD models [34, 48]. Surprisingly, in our hands APP/
PS-STZ-treated mice did not display increased CAA or SP
deposition in the cortex or the hippocampus, although we
did not specifically checked previously referred pathways,
and therefore, it is feasible that APP processing or the
AGEs/RAGE/NF-κB pathway could be affected. On the other
hand, we are aware of the limited amount of CAA in this
animal model at these early stages, which is mainly present
in leptomeningeal and penetrating vessels, while we usually
detect microhemorrhages deep in the parenchyma. To our
Fig. 5 Spontaneous bleeding is significantly increased in APP/PS1-STZ
mice. a Hemorrhage burden was significantly increased in the cortex
from Wt-STZ-treated mice and this effect was worsened in APP/PS1-
STZ-treated mice (**p<0.01 vs. the rest of the groups, ††p<0.01 vs.
Wt-Sham and APP/PS1-Sham). Individual hemorrhage size was similar
in all groups (p=0.69) under study, whereas a significant increase in the
number of hemorrhages per square millimeter was detected in Wt-STZ
mice; a worsening effect was observed in APP/PS1-STZmice (**p<0.01
vs. the rest of the groups, ††p<0.01 vs. Wt-Sham and APP/PS1-Sham). b
A similar trend was detected in the hippocampus, and STZ-treated mice
presented a significant increase in hemorrhage burden (††p<0.01 vs. Wt-
Sham and APP/PS1-Sham), due to an increase in the number of hemor-
rhages per square millimeter (††p<0.01 vs. Wt-Sham and APP/PS1-
Sham), while hemorrhage size was similar in all groups under study
(p=0.069). c Illustrative example of hemorrhages in cortical sections
from all groups under study, where a significant increase in hemorrhage
burden can be detected in APP/PS1-STZ mice. Green arrows point at
hemorrhages stained with Prussian blue and counterstained with neutral
red. Scale bar=100 μm. Insets show hemorrhagic areas in STZ and APP/
PS1-STZ mice, where light and dark blue spots can be identified as
earlier and older hemorrhages. Scale bar=25 μm. d Representative im-
ages of endothelium (red) and pericyte (green) immunostaining in all
groups under study. Scale bar=5 μm. We observed an slight, non signif-
icant, reduction in the amount of pericytes and endothelium cells in ves-
sels in APP/PS1-STZ mice (endothelium p=0.676, pericytes p=0.521)
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knowledge, no previous studies have focused on different Aβ
species, and in our hands, STZ-induced insulin depletion
slightly reduced SP and insoluble Aβ levels, whereas more
toxic soluble Aβ species were favored, as previously de-
scribed in other AD models with metabolic alterations [12].
It is also possible that increased soluble Aβ levels are an
intermediate step in the production of compact deposits, and
therefore, assessment of SP deposition at later time points may
result in increased Aβ deposition, as previously described
[47]. Since Aβ accumulation has been related to an imbalance
between production and degradation or clearance of the pep-
tide along perivascular spaces [17], it is also feasible that the
observed shift between soluble and insoluble Aβ levels could
be due to alterations in any step of the production-elimination
process. Following this idea, we analyzed IDE and neprilysin
levels in our animals, since Aβ and insulin degrading path-
ways tend to be reduced with age in AD patients. Previous
studies have revealed reduced levels and activities of Aβ and
insulin degrading enzymes in diabetic rats [49]; however, our
studies are in accordance with previous work on 5xFAD mice
in which IDE was not affected after STZ administration [48],
limiting a mechanistic approach in our study.
In order to explore other possibilities interfering in Aβ
elimination, we assessed the inflammatory process by ana-
lyzing microglial activation. We detected an overall increase
of microglial burden in APP/PS1 and STZ mice and similar
outcomes have been observed after STZ administration to
other animal models [50]. Also, this effect was more severe
in APP/PS1-STZ mice. We cannot exclude that earlier as-
sessment of the inflammatory process could have shown
greater differences, although mice ages and experimental
times were selected depending on Aβ pathology, STZ sur-
vival, and required time for T1D to fully develop. We also
observed that vascular damage, induced by STZ administra-
tion, was exacerbated in APP/PS1-STZ-treated mice and
hemorrhages were significantly increased in AD-diabetic
mice. Whereas the reductions observed in endothelial cells
and pericytes are limited, it remains possible that both added
alterations may be responsible, at least in part, for observed
vascular disease. Vascular alterations have been previously
described [50], although to our knowledge, the presence of
spontaneous bleeding has not been assessed in this AD-
diabetes model, and our results suggest a synergistic effect
between both pathologies. These data are in accordance
with epidemiological studies showing that vascular disease
is also a risk factor for dementia and that long-term hy-
perglycemia is associated with microvascular complications
[51]. Following this idea, it has been also shown that
cerebrovascular disease may worsen AD clinical symptoms
[52, 53], and it remains possible that blood-brain barrier
alterations may be responsible for the observed accumula-
tion of Aβ soluble species and learning and memory
dysfunction.
Conclusions
Altogether, our data suggest that APP/PS1-STZ-treated mice
present central alterations including exacerbated inflammation
and spontaneous bleeding. These independent and additive
adverse effects of STZ and APP/PS1 occurred with respect
to AD pathology and may underlie observed cognitive dys-
function. Therefore, it remains possible that by controlling
metabolic alterations, as previously suggested [19], central
pathological features could also be reduced.
Material and Methods
Animals
We used APPswe/PS1dE9 mice (Jackson Laboratory, Bar
Harbor, USA) as model of Alzheimer’s disease in this study.
In order to induce diabetes, mice were treated as previously
described [11].Mice (18 weeks old) were injected ip with STZ
(40 mg/kg) for five consecutive days and animals were aged
up to 26 weeks of age without insulin therapy. All experimen-
tal procedures were approved by the Animal Care and Use
Committee of the University of Cadiz, in accordance with
the Guidelines for Care and Use of Experimental Animals
(European Commission Directive 2010/63/UE and Spanish
Royal Decree RD 53/2013).
Metabolic Determinations
Body weight, postprandial blood glucose, and insulin levels
were determined at 18 (before the commencement of the treat-
ment) and 26weeks of age as previously described [11]. Brief-
ly, blood glucose levels were measured from nicked tails using
the glucometer Optium Xceed (Abbott, UK). Blood for plas-
ma insulin determination was collected from the tail vein into
capillary tubes precoated with potassium-EDTA (Sarstedt,
Nümbrecht, Germany). Blood samples were centrifuged dur-
ing 10 min, 6500 rpm at 4 °C, and plasma fraction was stored
at −80 °C until processed. Plasma insulin levels were mea-
sured using ultrasensitive mouse enzyme-linked immunosor-
bent assay (ALPCO Diagnostics, Salem, NH, USA).
MWM
Fourteen days prior to sacrifice, learning and memory abilities
were analyzed in the MWM test as previously described [11],
with minor modifications. Briefly, the maze consisted of a
round tank of water (0.95 m in diameter) with four equal
virtual quadrants indicated with geometric cues mounted on
the walls. An escape platform was located 2–3 cm below the
water surface and camouflaged with calcium carbonate to
cloud the water. Water temperature was 21±1 °C. A camera
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was mounted above the maze and attached to a computer and
Smart software (Panlab, Spain). Testing was conducted in two
phases: acquisition and retention. Acquisition consisted of
four trials per day for 4 days with the platform submerged.
During this phase, the platform was located in quadrant 2. The
time limit was 60 s/trial with an intertrial interval of 10 min. If
the animal did not find the platform, it was placed on it for
10 s. The retention phase took place 24 h (retention 1) and
72 h (retention 2) after finishing the acquisition phase. In this
phase, the submerged platform was removed, mice were
allowed to swim for 60s, and the time that mice spent in the
quadrant where the platform was previously located (quadrant
2) was recorded using SMARTsystem (Panlab, Spain). Swim-
ming velocity was also measured in order to detect any motor
activity dysfunction that could bias the learning and memory
assessment.
Motor Function and NOD Task
One day after finishing the MWM task, locomotor activity
was assessed in all animals under study as previously de-
scribed [54]. We measured the distance travelled by the mice
for 30 min in a transparent rectangular box (22-cm long×44-
cm width×40-cm high) using SMART system (Panlab,
Spain). In order to further assess anxiety-like behavior in our
mice, distance travelled was analyzed in the proximity of the
walls, as well as in the center of the boxes (10 cm from the
border). One day after actimetry, mice continued with the
NOD test to assess their episodic memory as previously de-
scribed [55]. On day 2 animals were exposed to two objects,
for habituation purposes, not used again during the object
exploration task on day 3. On day 3 each mouse received
two sample trials and a test trial. On the first sample trial, mice
were placed into the center of the box containing three copies
of a novel object (blue balls) arranged in a triangle-shaped
spatial configuration and allowed to explore them for 5 min.
After a delay of 30 min, the mice received a second sample
trial with four novel objects (red cones), arranged in a
quadratic-shaped spatial configuration, for 5 min. After a de-
lay of 30 min, the mice received a test trial with two copies of
the object from sample trial 2 (recent objects) placed in the
same position and two copies of the object from sample trial 1
(familiar objects): one of them in the same position (familiar
non-displaced object) and the other one in a new position
(familiar displaced object). Integrated episodic memory for
Bwhat,^ Bwhere,^ and Bwhen^ was analyzed as previously
described [55]: BWhat^ was defined as the difference in time
exploring familiar and recent objects, Bwhere^ was defined as
the difference in time exploring displaced and non-displaced
objects, and Bwhen^ was defined as the difference between
time exploring familiar non-displaced and recent non-
displaced objects. Motor function was also analyzed in the
rotarod (Panlab, Spain), as previously described [56], with
minor modifications. Briefly, mice were placed in the rotarod
facing away the experimenter. The rod accelerated from 0 to
30 rpm over 3 min and final revolutions per minute for each
mice were recorded.
Tissue Processing
At the end of the NOD test, mice were sacrificed by chloral
hydrate overdose (60 mg/kg). Brains were rapidly extracted
and weighed. Subsequently, hemispheres were separated: The
right hemisphere was dissected into the cortex and hippocam-
pus, which were preserved at −80 °C until used, and the left
hemisphere was immersed in 4 % paraformaldehyde for
2 weeks at 4 °C, to be then cut into 30-μm coronal sections,
for histochemical and immunohistochemical determinations.
Cresyl Violet Staining
We analyzed brain morphology by cresyl violet staining in
sections selected 1 mm apart (from 1.5 to −3.5 mm from
bregma) [57]. All six sections were used to analyze cortex
morphology and the last three sections were also used for
hippocampal studies. Briefly, sections were mounted and
dehydrated in 70 % ethanol for 15 min before incubation in
cresyl violet (Sigma, St. Louis, MO, USA) solution 0.5 % (w/
v) for 5 min. Sections were washed and fixed in 0.25 % acetic
acid in ethanol for 7 min and subsequent 100 % ethanol and
xylene for 2 min. Sections were mounted with DPX (Sigma,
St. Louis, MO, USA) photographed with a Laser Olympus U-
RFLT fluorescent microscope (Olympus, Japan). Images were
acquired using MMIcellTools software. Cortex and hippo-
campus sizes were measured using ImageJ software.
Prussian Blue Staining
Postmortem study of hemorrhages was performed by Prussian
blue iron staining and neutral red counterstain, as previously
describedwithminor modifications [11]. Briefly, adjacent sec-
tions to the ones used for cresyl violet staining were mounted
on slides and they were exposed to Prussian blue staining
(HCl 10% and potassium ferrocyanide 5%) for 30min. Then,
they were washed generously with water and rehydrated with
1-M phosphate buffer for 5 min. Subsequently, sections were
dehydrated in 70 % alcohol and immersed in a neutral red
solution 1 % (v/w) for 5 min. After washing, sections were
fixed in 95 % ethanol (with 1 % acetic acid) and immersed in
xylol for 4 min. Sections were mounted with DPX (Sigma, St.
Louis, MO, USA), coverslipped and photographed with an
Olympus U-RFL Laser-U fluorescent microscope (Olympus,
Japan). Cortical and hippocampal images were analyzed with
the free software ImageJ.
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Aβ ELISA Measurements
Soluble and insoluble Aβ40 and Aβ42 were quantified in the
cortex and hippocampus from groups under study using col-
orimetric ELISA kits (Wako, Japan, Aβ40 ref 294-62501 and
Aβ42 ref 290-62601) as previously described, with minor
modifications [20]. At each step, homogenization of 5–
10 mg of tissue in 50 ml of lysis buffer with protease inhibitor
cocktail (ref: 87787 and 87786, respectively, Thermo Scien-
tific Pierce, Spain) was followed by centrifugation at 14,
500 rpm for 12 min at 4 °C. Supernatants were retained for
soluble Aβ40 and 42 levels. The resultant pellet was then
extracted with 50 ml of 70 % formic acid in distilled water
and then centrifuged 10 min at 14,500 rpm at 4 °C, and this
fraction was neutralized with 1 M Tris (pH 11). Soluble and
insoluble fractions were diluted 1:10 and 1:30, respectively.
Standard curves were made using human Aβ40 and Aβ42
standards provided in the ELISA kit. Absorbance was mea-
sured spectrophotometrically at 450 nm (MQX200R2, Biotek
instruments, Burlington VT, USA) and data were expressed as
picomole per gram wet tissue.
Amyloid-Beta, Microglia, Endothelium, Pericytes,
and Neuronal Immunohistochemistry
APP/PS1-STZ and APP/PS1-Sham mice were assessed post-
mortem for Aβ burden in the cortex and hippocampus. Im-
munohistochemistry for Aβ was performed as previously de-
scribed [12] with minor modifications. PFA-fixed 30-μm sec-
tions were washed in PBS and pretreated with 70 % formic
acid for 10 min, and subsequently, they were blocked in 5 %
normal goat serum (NGS) and 0.5 % Triton-X 100 during 1 h.
Sections were immunostained with anti-Aβ17-24 antibody
1:2000 (4G8, Covance, Spain) and anti-IBA1 1:1000 (Wako,
Japan) in 1 % NGS overnight at 4 °C, followed by secondary
goat anti-rabbit conjugated to Alexa 488 and goat anti-mouse
to Alexa 595 (Invitrogen, USA) in 1 % NGS 1 h at room
temperature. Images were acquired using a Laser Olympus
U-RFL-T fluorescent microscope (Olympus, Japan) and
MMIcellTools software and analyzed with ImageJ software
to quantify Aβ burden as well as the number and size of
individual SP. CAA was also quantified as previously de-
scribed [20] and results were expressed as CAA burden (%
of affected vessel). Endothelium (anti-CD31, 1:100, BD Bio-
science, USA ) and pericyte (anti-NG2, 1:100, Millipore,
USA) immunostaining was performed in the same conditions.
Alexa Fluor anti-rat 594 and Alexa Fluor anti-rabbit 488 (Life
Technologies, USA) were used as secondary antibodies, re-
spectively, and percentage of vessel area covered by endothe-
lial cells or pericytes was quantified with ImageJ software.
Microglial activation was measured in the close proximity of
plaques (up to 50 μm from SP) as well as far from SP
(>50 μm), in the case of APP/PS1-Sham and APP/PS1-
STZ-treated mice. In the case of wild-type mice, the same
parameters were measured and compared with microglia far
from plaques in transgenic mice. Sections selected 1 mm apart
(from 1.5 to −3.5 mm from bregma), in all animals under
study, were coded and blind quantification was manually per-
formed in the regions of interest (cortex or hippocampus)
using ImageJ software. To quantify microglial burden (% area
covered), number of cells, and individual microglial size, the
final analysis included between 4500–6900 cells/group in the
cortex and 250–614 cells/group in the hippocampus. Contig-
uous sections that were used for neuronal immunostaining
were incubated in anti-NeuN antibody (Chemicon) 1:200,
and conjugated goat anti-mouse Alexa 594 was used as sec-
ondary antibody. Sections were washed and stained with 4′,6-
diamidino-2-phenylindole (DAPI) 1 mg/ml (Sigma) (1:2000)
and thioflavin S 0.001 %. The percentage of NeuN-positive
cells (normalized by total cells stained with DAPI) was quan-
tified in the proximity of SP in APP/PS1 and APP/PS1-STZ
mice (up to 50 μm). Areas located far from SP were also
compared with wild type and wild-type-STZ mice using Im-
age J software.
IDE, Neprilysin, Total Tau, and Phospho-tau Levels
Western blot for IDE, NEP, phospho-tau, and total-tau levels
was performed in fresh tissue as previously described [12].
Briefly, 5–10 mg of tissue from the cortex and hippocampus
was pretreated in lysis buffer (Cell Signaling, USA) contain-
ing protease inhibitors and phosphatase inhibitors (Sigma,
USA). Protein (80 μg) in the case of total and phospho-tau,
and 160 μg in the case of IDE and NEP, was loaded and
separated on 10 % acrylamide-bisacrylamide gels. Proteins
were transferred to PVDF membranes. Membranes were then
immersed in blocking buffer (Invitrogen) for 1 h and incubat-
ed overnight at 4 °C with primary antibodies anti-total tau
(1:1000; DAKO, Glostrup, Denmark), anti-phospho-tau
(1:1000, clone AT8; Fisher Scientific, Waltham, MA, USA),
anti-IDE (1:1000, N-Terminal 97-273, PC730, Millipore),
anti-NEP (1:1000, ab951, Abcam), and anti-β-actin (1:2,
500,000, Sigma). Membranes were washed and then incubat-
ed with a chemiluminescent immunodetection system for pri-
mary antibodies for mouse (AT8, anti-IDE, and anti-β-actin)
or for rabbit (anti-total tau and anti-NEP) (Invitrogen, Carls-
bad, USA) for 1 h. Signal was detected using Novex AP
Chemiluminescent Substrate (Invitrogen, Carlsbad, USA)
and Kodak Biomax Light Film (Sigma, USA). Subsequent
primary antibody incubations were preceded by stripping,
using Western Blot Stripping Buffer (Fisher Scientific, Wal-
tham, MA, USA) for 10 min at 37 °C in agitation. Immuno-
blots were semi-quantified by measuring the optical density
(OD) of each protein band on scanned film using the ImageJ
software. Data were represented as percentage of wild-type-
Sham values.
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Statistical Analysis
Two-way ANOVA was performed to compare the acquisition
phase in the MWM test. Further differences in the MWM and
the NOD tests, as well as in postmortem studies (histology,
immunohistochemistry, and Western blot), were determined by
one-way ANOVA followed by Tukey b or Tamhane tests as
required. When only two groups (APP/PS1-Sham and APP/
PS1-STZ) were under study, differences were detected by Stu-
dent’s t test for independent samples, whereas one-wayANOVA
was used when more than two groups were under study. SPSS
v.15 software package was used for all statistical analysis.
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